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Vigabatrin (VGB) has been shown in a number of clinical trials with varying designs to be effective and well-tolerated as
both add-on therapy and monotherapy in epilepsy with partial seizures with or without secondary generalization as well as in
infantile spasms. The present study is an open, long-term (1 year) extension of a randomized double-blind placebo-controlled
multicentre Canadian trial of VGB in resistant partial adult epilepsy. The present study was designed to examine the safety and
long-term efficacy of VGB.
Completers of the preceding double-blind study had their dose of VGB titrated to 4 g/day over 3 weeks. Patients were
evaluated every 2–4 weeks and at week 14 were allowed to continue only if they achieved a 50% seizure reduction compared
with pre-VGB baseline. In addition to neurological and physical examinations, safety was assessed by a cognitive psychosocial
test battery, visual and somatosensory evoked potentials and MRI scans.
Ninety-seven of 100 eligible patients entered the study, 53 of whom completed the 52 weeks. Fifty-eight percent of the
patients had a greater than 50% seizure reduction in seizures vs. pre-VGB baseline. Seizure reductions of 56% and 45%,
respectively, were seen in the VGB and placebo groups from the preceding study. Fifty-four percent of patients were judged
by the investigators to have experienced at least a moderate therapeutic effect. Discontinuations were 29% for lack of efficacy
and 12% for adverse effects. There was a mean weight gain of 3.7 ± 0.2 kg by end of study. Neurological/psychiatric side
effects were the most common reason for withdrawal including three behavioral reactions attributed to the drug which required
temporary hospitalization. There were no abnormalities on laboratory or special tests and there was a tendency for improvement
on most tests of cognitive function and mood.
Vigabatrin, as an add-on agent, is well-tolerated and can be of long-term benefit in a substantial proportion of patients with
intractable partial epilepsy.
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INTRODUCTION
Vigabatrin (VGB) is an irreversible GABA transami-
nase inhibitor which produces a two- to three-fold rise
in brain GABA concentration. It has been shown to be
effective, both as an add-on agent and in monother-
apy, in controlled blinded clinical trials in resistant
and newly-diagnosed epilepsy1–24. A previous Cana-
dian multicentre double-blind study of VGB (protocol
−021) reported a 48% responder rate and 52% me-
dian partial seizure reduction in adults with uncon-
trolled partial and secondarily generalized seizures25.
The present study was an open follow-up study to eval-
uate the long-term safety and efficacy of vigabatrin
in completers of the double-blind Canadian vigabatrin
study.
∗Editor’s note: the attention of UK readers is drawn to recent suggested restriction on the use of vigabatrin related to the potential side effect of
peripheral visual loss.
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MATERIALS AND METHODS
Inclusion/exclusion criteria
Completers of the double-blind (−021) study, 16 years
of age or older, were allowed to enter the study.
The patient population characteristics from which the
present study drew its participants are described in
the publication of the results of the previous study
(Bruni et al. submitted for publication). These patients
were adult patients with intractable longstanding par-
tial epilepsy. Women of child-bearing potential were
required to continue effective contraception, to sign a
pregnancy waiver and undergo a pregnancy test prior
to entry. Patients with a treatable cause of seizures
or progressive neurological disorder; previous cranial
radiotherapy; a history of frequent status epilepticus
(>1 episode in preceding 6 months); significant active
medical illness; significant past or present psychiatric
illness, drug or alcohol abuse; non-compliance or in-
ability to record seizures or take medication properly
or known allergy to vigabatrin were all excluded from
the study.
Study design
All patients signed written informed consent for the
study, which had been approved by individual hospital
research ethics boards. This was a multicentre study
which included 10 Canadian epilepsy centres. Patients
who were seizure free in the previous double-blind
study at doses of VGB below 4 g/day were unblinded
and allowed to continue with the same dose in the
present open study. Patients who received 4 g/day in
the preceding study, whether or not they were seizure
free, were continued at that dose. Placebo patients en-
tered the study at 1 g/day and all other patients at
2 g/day. Dosage was titrated upward in double-blind
fashion by 1 g/day at weekly intervals and all patients
were receiving 2 g b.i.d. by the third week of this study.
The dose of VGB could be reduced due to adverse ef-
fects after that point.
Patients were seen and evaluated at weeks 2, 4,
6, 10, 14, 18, 22 (only if the patient was being ta-
pered off the study drug), 26, 38 and 52. Evaluation
included physical and neurological exams, study and
concomitant drug records, blood biochemistry, hema-
tology, concomitant AED levels, adverse event record-
ing and seizure counts. A cognitive psychosocial test
battery was done consisting of the following stan-
dardized tests: Lafayette Grooved Pegboard, Stroop
Test, Benton Visual Retention Test, Controlled Oral
Word Association Test, Symbol Digit Modalities, Rey
Auditory Verbal Learning Test, Wonderlic Personnel
Test, Digit Cancellation, Mood Rating Scale, Profile of
Mood States and the Washington Psychosocial Seizure
Inventory. Pattern-reversal visual and median nerve
somatosensory evoked potentials and MRI scanning
(at selected centres where the test was available) were
performed at study termination and week 6 (except
MRI). At week 14 only those patients achieving a 50%
or greater reduction of seizures on VGB compared
with the baseline of the preceding double-blind study
were allowed to continue. Other patients were tapered
off the vigabatrin by 0.5 g/week.
Efficacy outcome measures
The efficacy outcome measures which were used
were: median monthly reduction in total seizure fre-
quency, percentage of responders (≥50% seizure re-
duction), seizure-free days per month, percentage of
patients seizure free and physician’s global assess-
ment. Measurements were compared for the baseline
period of the double-blind (−021) study, end of the
double-blind study, the dose adjustment phase of the
open study and the initial and the last 8 weeks of the
open study.
RESULTS
Patient disposition
One hundred of the 111 patients entering the double-
blind study completed the protocol, 52 on VGB and 48
on placebo and were eligible for entry into the open
study (Table 1). Ninety-seven of these entered the open
study, 95 of whom reached a VGB dose of 3 or 4 g/day
and 53 of whom completed the 52 weeks of the study
(49 on 4 g/day). The three patients who did not enter
the study dropped out for personal or administrative
reasons.
Efficacy
Responder rates (intention-to-treat) comparing the last
8 weeks of this open study with the baseline (pre-
VGB) as well as with the end of the double-blind
study, were 58% and 41%, respectively. There was
an 85% responder rate among those completing the
present study (Table 2). All responders in the double-
blind study maintained their response in the open
study, although not all stayed on the drug. Sixty per-
cent of those in the placebo group from the double-
blind study were responders by the end of the open
study. The increase in seizure-free days per 28 days is
also shown in Table 2 for the same time periods.
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Table 1: Patient disposition in open-label study (022) according to treatment in preceding double-blind study (021).
Placebo in 021 Vigabatrin in 021 All patients
n (%) n (%) n (%)
Entered study 47 50 97
Completed study 27 (57) 26 (52) 53 (55)
Withdrawalsa 20 (43) 24 (48) 44 (45)
• Lack of benefit 10 (21) 18 (36) 28 (29)
• Adverse events 8 (17) 4 (8) 12 (12)
• Worsening of seizures 1 (2) 0 (0) 1 (1)
• Surgery 0 (0) 1 (2) 1 (1)
• Otherb 2 (4) 4 (8) 6 (6)
a Withdrawal was for more than one reason in four cases.
b Pregnancy (1), voluntary withdrawal (3), investigation for surgery (2).
Table 2: Efficacy of vigabatrin at end of study of the
open-label study (022) compared with the baseline in the
preceding double-blind study (021).
Patient group ≥50% Seizure Increase in
reductiona seizure-free days
n (%) (number/28 days)
022-Intention-to-treat
(n = 97) 56/97 (58) 3.7± 0.1
022-Study completers
(n = 53) 45/53 (85) 4.8± 0.1
021-End of study
(n = 111) 41% 2.2± 0.1
a ≥50% seizure reduction in complex partial seizures plus partial
seizures secondarily generalized (IB + IC).
Table 3: Comparison of seizure-free patients at the end of the
preceding double-blind study (021) and at the end of the
open-label study (022).
Seizure freea Seizure freea
at end of 021 at end of 022
n Yes No
Yes 10 4/10 (40%) 6/10 (60%)
No 87 7/87 (8%) 80/87 (92%)
a Seizure free is defined as no seizures during the last 8 weeks of
the study or evaluated as seizure free in the physician’s final
evaluation.
Table 4: End of study physician’s assessments of therapeutic
effect and global evaluation (intention-to-treat, n = 97).
Therapeutic Global
effect evaluationa
n (%) n (%)
Seizure free 7 (7)
Marked improvement 19 (20) 25 (26)
Moderate improvement 26 (27) 20 (21)
Minimal—no improvement 38 (39) 40 (41)
Worse 7 (7) 12 (12)
a Global evaluation included an assessment of both efficacy and
tolerability.
The median total seizures per 28 days (complex par-
tial plus secondarily generalized) for various phases of
the study is shown in Fig. 1. The data for patients re-
ceiving placebo or VGB in the double-blind study is
shown separately for the open study. Comparing end
of study with baseline for the VGB group and end of
study with end of double-blind study for the placebo
group, we note comparable seizure reduction of 5/9
(56%) and 3.3/7.3 (45%), respectively. Eleven out of
97 (11%) patients were seizure free by the end of the
open study, four of whom were seizure free at the end
of the double-blind study. An additional six patients
who had been seizure free entering the open phase
were no longer seizure free by the end of the study (Ta-
ble 3). There was no significant correlation between
mean trough VGB plasma concentrations and thera-
peutic outcome judged by responder rate or median
percentage seizure reduction.
Physician’s assessments of therapeutic effect at end
of study show that 54% of patients had experienced
at least a moderate therapeutic effect and 47% were
judged to be globally at least moderately better off on
the drug (Table 4). There were no significant differ-
ences between the study completers (n = 53) and the
intention-to-treat group (n = 97) according to median
age, gender, median age at onset of epilepsy, duration
of epilepsy, weight or whether they derived from the
placebo or treatment group in the double-blind study.
Compliance, determined by pill counts and patient
reports, and defined as total tablets taken/total tablets
prescribed, was 88%.
Drug interactions
There were mean decreases in phenobarbital and
phenytoin plasma levels of 11% and 22%, respec-
tively, by end of study compared with baseline.
Safety and tolerability
There were no effects on physical examination or vital
signs. Ophthalmological examinations did not reveal
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Fig. 1: Seizure rates of complex partial seizures plus partial seizures secondarily generalized (IB + IC) across different study
phases (intention-to-treat).
Table 5: Treatment-related adverse events reported by ≥10% of patients by severity (n = 97).
Adverse event
(all were judged Severitya
possibly or probably Mild Moderate Severe Total
related to VGB) n (%) n (%) n (%) n (%)
Fatigue 21 (22) 11 (11) 1 (1) 25 (26)
Headache 13 (13) 17 (18) 1 (1) 25 (26)
Dizziness 18 (19) 6 (6) 2 (2) 22 (23)
Amnesia 14 (14) 9 (9) 0 (0) 19 (20)
Agitation 7 (7) 9 (9) 3 (3) 14 (14)
Nystagmus 12 (12) 2 (2) 0 (0) 13 (13)
Drowsiness 6 (6) 7 (7) 2 (2) 11 (11)
a In some cases, patients may have experienced an adverse event in more than one severity category. As such, the sum of patients in each
severity assessment may exceed the total number of patients.
any clinically important effects of vigabatrin on vi-
sual function, retinal vessels, the macula or optic nerve
head. No effects were seen on visual fields tested by
confrontation. The adverse events and their severity re-
ported by at least 10% of patients are shown in Table 5.
All of these fell into the neurological/behavioral cate-
gory and many were not persistent. The vast majority
of these were judged to be mild and none were judged
to be ‘definitely’ related to vigabatrin by the inves-
tigators. Comparing baseline (pre-VGB) with end of
study, there was a mean weight gain of 3.7 ± 0.2 kg.
Thirty-nine percent of patients gained ≥7% of their
body weight, although 17% of patients experienced a
weight reduction during the study.
There were 44 patients (45%) who were discon-
tinued from the study: 28 (29%) for lack of clinical
benefit, 1 for worsening of seizures, 12 (12%) due
to adverse events and 7 (7%) for other reasons (Ta-
ble 1). Four patients had two reasons for withdrawal.
All adverse events leading to discontinuation were in
the neurological/psychiatric category. Four of the pa-
tients discontinuing vigabatrin due to adverse events
had been on the drug for over 45 weeks. There were
12 hospitalizations including 15 events classified as
serious. In only 4/12 cases, all with behavioral events,
were the adverse events judged to be possibly (1),
probably (2) or definitely (1) related to VGB. A sum-
mary of the adverse events leading to hospitalization is
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Table 6: Summary of all adverse events leading to hospitalization.
Patient’s Treatment in Event (s) Duration of VGB Physician’s Outcome
age/gender 021 treatmenta assessment of
(weeks) relationship
18/F Placebo Tonic–clonic status epilepticus 60 Possible Recovered
37/F Placebo Post-ictal delirium 2 Probable Recovered
48/F Placebo Suicidal ideation 6 Probable Recovered
50/F Vigabatrin Hyponatremia 40 Other cause Recovered
Confusion/delusions 67 Other cause Recovered
Fracture pathological 87 Other cause Recovered
19/M Vigabatrin Increased seizure frequency and intensity 74 Other cause Recovered
34/F Placebo Aggressive behavior 18 Other cause Recovered
32/F Placebo Psychosis 11 Definite Recovered
22/F Vigabatrin Hematoma 73 Other cause Recovered
34/F Placebo Post-ictal aggressiveness 11 Other cause Recovered
47/F Placebo Intestinal obstruction 28 Other cause Recovered
Walking difficulty 30 Other cause Recovered
39/M Placebo Increased seizure frequency and intensity 3 Other cause Recovered
37/F Placebo Aspiration pneumonia 35 Other cause Recovered
a Duration of VGB treatment is defined as patient’s total exposure to vigabatrin in study 021 and 022 prior to an event resulting in
hospitalization.
Table 7: End of study physician’s overall assessment of
tolerability.
Intention- Study
to-treat completers
(n = 97) (n = 53)
Assessment n (%) n (%)
Extremely well tolerated 28 (29) 19 (36)
Well tolerated 38 (39) 25 (47)
Fairly well tolerated 20 (21) 8 (15)
Total well tolerated 86 (89) 52 (98)
Total not well tolerated 11 (11) 1 (2)
Table 8: Psychosocial and cognitive test resultsa (n = 84).
Mood and adjustment Cognition
(21 scores) (21 scores)
Improvement 14 15
Worsening 5 5
No change 2 1
a Mood and adjustment (3 tests, 21 scores) and cognitive (8 tests,
21 scores) assessments were administered at mid-study and end of
study. Test results are compared with baseline (pre-randomization
of preceding double-blind study (021)).
shown in Table 6. Physicians’ overall assessments of
patient tolerability at end of study showed that the drug
was judged to be extremely well-tolerated in 29%,
well-tolerated in 39%, fairly well-tolerated in 21% and
not well-tolerated in 11% of the patients (Table 7).
Cognitive and psychosocial test battery results at
mid-study and end of study compared with baseline
did not show any consistent worsening trends in any
of the scales or subtests. Fourteen of 21 scores on the
mood and adjustment scales showed improvement and
five showed worsening. Fifteen of 21 scores on the
cognitive tests showed improvement and five showed
worsening (Table 8).
Clinical laboratory results were generally unre-
markable and no patient was discontinued due to an
abnormal laboratory value. SGPT/ALT levels were
markedly reduced and SGPT/AST levels were mini-
mally reduced. This previously-observed effect is be-
lieved to result from a nonspecific transaminase inhi-
bition by vigabatrin. MRI studies were completed at
pre-VGB baseline and end of study in 57 patients. No
abnormalities or changes suggestive of intramyelinic
edema were observed. The mean percentage change in
evoked potential latencies was not increased at end of
study compared with baseline.
DISCUSSION
In this one-year open follow-up study of previously
intractable epilepsy patients who had vigabatrin added
on to their previous antiepileptic drugs, 53/97 (55%)
completed the 12 months of the study and 85% of
these had ≥50% seizure reduction. Twenty-six of the
53 completers had received vigabatrin in the preceding
double-blind study, meaning that they had been on the
drug for nearly 2 years. Sixty percent of the placebo
group in the preceding−021 study achieved therapeu-
tic success (≥50% seizure reduction) in the present
study and all of the vigabatrin responders in the −021
study maintained their response to the end of the
present study. The overall responder rate (intention-
to-treat) of 56/97 (58%) is similar to what has been
reported in several other double-blind and open stud-
ies10, 13, 20, 24. The mean increase in seizure-free days
was 3.7 days per 4-week period for the 97 patients.
Eleven patients (11%) were seizure free by the end of
the study. In 46% of the cases, physicians felt that they
were moderately or markedly globally improved com-
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pared with 12% of the cases who were judged to be
worse overall. It appears from our results that toler-
ance to the effects of vigabatrin was not a significant
factor. The question of tolerance, which is common
with benzodiazepines also acting by a GABAergic, al-
though different, mechanism has been debated by pre-
vious authors. However, the tendency for responses to
be retained in several long-term VGB studies suggests
that tolerance is minimal15, 26–30.
Adverse events in this study were generally mild and
were mainly of the ‘acute neurotoxic’ type (e.g. fa-
tigue, headache, dizziness) which are relatively com-
mon in this patient population even when placebo is
employed31–35. Physicians judged that in 68% of pa-
tients the drug was well tolerated or extremely well
tolerated compared with only 11% in whom it was
not well tolerated. The mild weight gain over the du-
ration of the study was not clinically significant and
no patient withdrew for this reason. Psychosocial and
cognitive test results revealed a tendency for both
mood/adjustment and cognitive scores to improve dur-
ing the study. Specific studies examining the cognitive
effects of vigabatrin have shown that it does not cause
cognitive impairment in a variety of test batteries at
therapeutic doses36–38. Only 13 of the 44 withdrawals
(30%) were due to adverse events (including seizure
exacerbation in 1/13). The 12 other withdrawals were
all for neurological or behavioral side effects. Of the
12 patients who had adverse events leading to hospi-
talization, in only 4/12 did the physician implicate vi-
gabatrin as a possible, probable or definite cause and
3/4 involved a behavioral adverse event. This 3% in-
cidence of serious behavioral toxicity parallels the in-
cidences mentioned in several other studies39–43. The
behavioral reactions in these three cases were quite
varied. One was a post-ictal delirium/psychosis, one
a severe depression and one a psychotic reaction, sug-
gesting that the behavioral reactions on vigabatrin may
be of varied pathogenesis. The three patients had all re-
ceived placebo in the preceding study and had been re-
ceiving vigabatrin for 4, 6 and 11 weeks. All recovered
rapidly once the drug was withdrawn. There were no
adverse effects during the one-year period of the study
on physical examination findings, clinical/laboratory
testing, evoked potentials or brain MRI scan.
In an open study, such as this, tolerability and sus-
tained response to the drug are the two most important
measures. We have shown that vigabatrin is exceed-
ingly well-tolerated in this group of intractable adult
epileptic patients, even when used in polytherapy. The
results also show that the drug can be of long-term
sustained benefit in a substantial proportion of adult
patients with partial epilepsy who have not responded
to conventional therapy.
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